Patent ID: 11952376
Assignee: PLIANT THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 150:
151. The method of claim 148, wherein:
(i) modulating the activity of at least one integrin is inhibiting the activity of αvβ1 integrin; or
(ii) modulating the activity of at least one integrin is inhibiting the activity of αvβ6 integrin; or
(iii) modulating the activity of at least one integrin is inhibiting the activity of both αvβ1 integrin and αvβ6 integrin; and
(iv) the individual has or is at risk of having a fibrotic disease or fibrotic condition selected from the group consisting of alcoholic liver disease induced fibrosis, Alport syndrome, biliary atresia, chronic kidney disease, Crohn's disease, diabetic kidney disease, diabetic nephropathy, focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis (IPF), interstitial lung disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), primary biliary cholangitis, primary sclerosing cholangitis (PSC), radiation-induced pulmonary fibrosis, scleroderma, and systemic sclerosis associated interstitial lung disease.